GRI Bio warns of substantial doubt about its ability to continue as a going concern due to ongoing losses and clinical funding needs.
SEC EDGAR, 2026-11-13: 10-Q — "substantial doubt", "material weakness"
GRI Bio warns of substantial doubt about its ability to continue as a going concern due to ongoing losses and clinical funding needs.
Company: GRI Bio, Inc. (GRI) Filed: 2026-11-13, 10-Q (Item none) Phrase: "substantial doubt" — "Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements." What the filing says: GRI Bio reports that its cash and cash equivalents of $9.472 million as of September 30, 2026, will only fund planned operations through the second quarter of 2027, assuming only preliminary work on its lead product candidate, GRI-0621. Completing dose-ranging and other clinical studies for GRI-0621 will require substantial additional capital. The company has accumulated a deficit of $56.843 million since its 2009 inception and expects to continue incurring significant operating losses. Furthermore, its market value of listed securities is currently under $5 million, which risks immediate delisting if Nasdaq's stayed MVLS requirement becomes effective. Two ways it goes: A. The company secures additional equity financing, debt, or strategic partnerships to fund its clinical programs and maintain its Nasdaq listing. B. The company fails to raise capital or faces delisting, forcing it to scale back, delay, or entirely cease its operations. Next date: none named Watch: SEC or Nasdaq announcements regarding the stayed MVLS requirement, or company filings disclosing new financing or strategic partnerships. Tags: going concern